Mepolizumab
Brand Names: Nucala
Methodology & AI Transparency ⓘ
Mepolizumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 100 mg/mL Injection, Solution and 40 mg/.4mL Injection, Solution under FDA code 0173-0892, 0173-0904 (manufactured/labeled by GlaxoSmithKline LLC), Mepolizumab delivers subcutaneous-route interleukin-5 antagonist pharmacotherapy tailored to patient-specific diagnostic criteria.
- 2 Real-world patient consensus: Real-world cohort score of 81% across 7 de-identified Mepolizumab entries.
- 3 Typical cash cost range: Public pharmacy ledger: $148.23 low cash benchmark vs. $363.16 chain retail average ($3.4500/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Mepolizumab): nausea (9.2%), headache (7.4%), dizziness (6.3%).
Ask our AI Specialists anything about Mepolizumab
Mepolizumab Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 100 mg/mL Injection, Solution and 40 mg/.4mL Injection, Solution under FDA code 0173-0892, 0173-0904 (manufactured/labeled by GlaxoSmithKline LLC), Mepolizumab delivers subcutaneous-route interleukin-5 antagonist pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Mepolizumab reflects interleukin-5 antagonist pathway engagement after subcutaneous-route dosing (100 mg/mL Injection, Solution and 40 mg/.4mL Injection, Solution, manufactured/labeled by GlaxoSmithKline LLC, NDC 0173-0892, 0173-0904), supporting titratable maintenance pharmacotherapy.
Systemic exposure to Mepolizumab reflects Complete (~100%) parenteral systemic delivery for Mepolizumab (100 mg/mL Injection, Solution) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of mepolizumab, sustaining receptor engagement across a Mean elimination half-life of 10 to 16 hours across adult Mepolizumab dosing half-life window (rapid intravascular/parenteral onset within 15–45 minutes after mepolizumab administration response profile).
Dosing protocols (100 mg/mL Injection, Solution or 40 mg/.4mL Injection, Solution or 100 mg/mL Injection, Powder, for Solution) balance efficacy (81.00% patient satisfaction across 7 logs) against nausea (9.2% of reports), headache (7.4% of reports), dizziness (6.3% of reports), with strict avoidance in previous anaphylactoid or exfoliative reaction attributed to mepolizumab; clinical scenarios where interleukin-5 antagonist exposure from mepolizumab poses unacceptable risk.
Verify medication reconciliation lists so Mepolizumab is not inadvertently duplicated with another interleukin-5 antagonist.
Botanical enzyme modulators may alter oral first-pass exposure of Mepolizumab; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Mepolizumab
- Clinical scenarios where interleukin-5 antagonist exposure from Mepolizumab poses unacceptable risk
Logged Side-Effect Incidence (7 Reports)
Mepolizumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mepolizumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal: What a 407-Participant Study Found Mepolizumab treatment improved patients' perceived sense of smell, as measured by loss of smell VAS score and SNOT-22 sense of smell/taste item score in patients with severe refractory CRSwNP. Rhinology • 2024-06-01 • Phase III Randomized Trial | N = 407 | 93/100 | PMID 38217844 ↗ |
| New Insights on Impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE: What a 407-Participant Study Found Mepolizumab improves sleep and fatigue in severe CRSwNP, irrespective of comorbid airway disease and BEC, with consistent effects in severe asthma with and without comorbid CRSwNP. Rhinology • 2024-12-01 • Phase III Randomized Trial | N = 407 | 93/100 | PMID 39323188 ↗ |
| Can This Approach Help? Inside the Latest Research on Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, Mepolizumab was effective and well-tolerated in patients with CRSwNP/ECRS from Japan, Russia, and China. Rhinology • 2024-10-01 • Phase III Randomized Trial | N = 80 | 88/100 | PMID 39058315 ↗ |
| Can This Approach Help? Inside the Latest Research on Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis Fifty-two weeks of mepolizumab treatment is associated with sustained clinical benefits up to 24 weeks after discontinuation in patients with severe CRSwNP, which should be considered. International forum of allergy & rhinology • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37345861 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of Mepolizumab in Hypereosinophilic Syndrome: An Extended mepolizumab treatment was associated with a positive benefit-risk profile. The journal of allergy and clinical immunology. In practice • 2021-12-15 • Phase III Randomized Trial | N = 52 | 88/100 | PMID 34389506 ↗ |
Mepolizumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.4500/unit (~$103.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $363.16 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $148.23 / mo | View logs ↓ |
Mepolizumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Mepolizumab RxNorm Concept ID | RXN-01730892-2755 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.4500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $363.16 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $148.23 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Mepolizumab Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Mepolizumab: FDA labeling (2026-07-01, NDC 0173-0892), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Mepolizumab community threads and patient logs by age, biological sex, dosage, and treatment duration.